COVID-19 Vaccine Results A Breakthrough Moment For BioNTech
Founder Considers Its Focus To Be Immunotherapy, Not mRNA
Approval for the first-to-market COVID-19 vaccine would transform BioNTech – but major challenges in meeting global demand and for its oncology pipeline await.
You may also be interested in...
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
Join us for a brief audio tour around key developments in the global biopharma industry over the past week, in this podcast version of Scrip's Five Must-Know Things.
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.